Platelet Activation and Responsiveness in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD)
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 主要终点
- Platelet activation: platelet expression of CD62P (P-selectin) and fibrinogen binding at baseline and upon ex vivo stimulation.
研究概览
简要总结
Chronic obstructive pulmonary disease (COPD) is known for development of severe cardiovascular co-morbidities. Systemic inflammation during acute exacerbations of COPD (AE-COPD) is thought to play a role in development of cardiovascular disease. Platelets contribute to acute cardiovascular events and atherosclerosis. When platelets are activated, they form complexes with monocytes. These platelet-monocyte complexes (PMCs) are an early process in atherothrombosis and promote inflammation. In COPD, platelet function in AE-COPD is scarcely studied. This study aims to address this gap by investigating platelet function and coagulation in patients with AE-COPD and after convalescence.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>40 years
- •Spirometry confirmed diagnosis of COPD (i.e. post-bronchodilator FEV1/FVC < 70% and less than 12% on reversibility testing< Lower limit of normal (LLN))
- •≥10 pack years of smoking
排除标准
- •Use of anti-coagulation or other platelet function inhibitors
- •Chronic inflammatory diseases, for example rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE)
- •Malignancies
结局指标
主要结局
Platelet activation: platelet expression of CD62P (P-selectin) and fibrinogen binding at baseline and upon ex vivo stimulation.
时间窗: Measured at presentation with an AE-COPD and after 8 weeks
次要结局
- Platelet-monocyte interaction (CD14 cells positive for CD61)(Measured at presentation with an AE-COPD and after 8 weeks)
- Monocyte activation (CD11b expression on CD14 positive cells)(Measured at presentation with an AE-COPD and after 8 weeks)
- Plasma markers: Interleukin-6, Interleukin-8, high sensitive-CRP, soluble P-selectin, soluble Fibrinogen, D-dimer(Measured at presentation with an AE-COPD and after 8 weeks)
- Tissue factor triggered thrombin generation capacity(Measured at presentation with an AE-COPD and after 8 weeks)